Fact Sheet: President Donald J. Trump Announces Second Deal to Bring Most-Favored-Nation Pricing to American Patients

10/10/2025

Fact Sheets

View Original

Action Summary

MFN Pricing Initiative: President Trump announced the second agreement with AstraZeneca to align American drug prices with the lowest prices paid by other developed nations, ensuring MFN (most-favored-nation) pricing for State Medicaid programs.
Cost Savings for Patients: The agreement is expected to yield hundreds of millions in savings, benefiting 9 million patients on AstraZeneca medications as well as millions more suffering from asthma (25 million) and COPD (16 million); key products include BEVESPI AEROSPHERE, BREZTRI AEROSPHERE, and AIRSUPRA with significant direct purchase discounts.
Repatriation and Discount Requirements: AstraZeneca must repatriate increased foreign revenue on existing products and offer deep discounts off list prices when selling directly to American patients.
Domestic Investment in Pharmaceutical Supply Chains: AstraZeneca will invest $50 billion in U.S. manufacturing and R&D, including building a new facility in Charlottesville, Virginia, which is expected to create 3,600 high-skilled jobs.
Countering Global Pricing Imbalances: The action aims to stop foreign countries from benefiting from American pharmaceutical innovation by ensuring that new drugs are priced at MFN rates, thereby rebalancing costs that Americans currently subsidize through higher domestic prices.
Historical Context and Additional Actions: This agreement follows previous initiatives—an Executive Order on MFN Prescription Drug Pricing (May 12, 2025) and letters sent to pharmaceutical manufacturers (July 31, 2025), as well as an earlier MFN agreement with Pfizer (September 30, 2025)—demonstrating the administration’s ongoing efforts to lower prescription drug costs for American patients.

Risks & Considerations

The Executive Order on Most-Favored-Nation (MFN) pricing could lead to significant changes in the pharmaceutical industry, impacting research funding and partnerships at Vanderbilt University. The focus on reducing drug prices may affect the financial dynamics of pharmaceutical collaborations.
Vanderbilt’s medical research programs might face challenges if pharmaceutical companies reduce their investment in research and development due to decreased revenue from lower drug prices.
The emphasis on American patients and the potential reduction in drug prices could lead to increased demand for healthcare services, impacting Vanderbilt’s medical facilities and programs.
There is a risk that the focus on domestic pharmaceutical manufacturing and investment could shift resources away from international collaborations, affecting Vanderbilt’s global research initiatives.

Impacted Programs

Vanderbilt University Medical Center may experience changes in drug procurement costs, potentially affecting budgeting and financial planning.
The School of Medicine could see shifts in research funding opportunities, particularly if pharmaceutical companies adjust their investment strategies in response to the MFN pricing policy.
Vanderbilt’s Research Centers focusing on pharmaceutical and healthcare innovation may need to adapt to new funding landscapes and explore alternative partnerships.
The Office of Federal Relations might need to engage more actively with policymakers to understand and influence the implications of the MFN pricing policy on university programs.

Financial Impact

The reduction in drug prices could lead to cost savings for Vanderbilt’s healthcare facilities, potentially allowing for reallocation of resources to other areas of need.
However, the potential decrease in pharmaceutical company revenues might result in reduced funding for collaborative research projects, impacting Vanderbilt’s research budget.
Vanderbilt may need to explore new funding sources or partnerships to offset any potential decrease in pharmaceutical research funding.
The focus on domestic manufacturing and investment could present opportunities for Vanderbilt to engage in new research and development initiatives within the U.S.

Relevance Score: 3 (The order presents moderate risks involving compliance and potential shifts in research funding and partnerships.)

Key Actions

Vanderbilt University Medical Center (VUMC) should evaluate the impact of the Most-Favored-Nation (MFN) pricing on its pharmaceutical procurement strategies. By understanding the cost savings from reduced drug prices, VUMC can optimize its budget allocation for patient care and research initiatives.
The Office of Federal Relations should engage with policymakers to ensure that Vanderbilt’s interests are represented in ongoing discussions about pharmaceutical pricing and healthcare policy. This engagement can help the university influence future policy developments that affect healthcare costs and access.
Vanderbilt’s School of Medicine should explore research opportunities related to the economic and health impacts of MFN pricing. By conducting studies on cost savings and patient outcomes, the school can contribute valuable insights to the national conversation on drug pricing reform.
The Department of Economics should analyze the broader economic implications of the MFN pricing policy. This analysis can provide a deeper understanding of how changes in drug pricing affect the healthcare market and the economy as a whole.
Vanderbilt’s Center for Health Policy should assess the potential effects of MFN pricing on healthcare access and equity. By examining how reduced drug prices impact different populations, the center can offer policy recommendations to ensure that cost savings translate into improved healthcare access for all.

Opportunities

The MFN pricing agreement presents an opportunity for Vanderbilt University to strengthen partnerships with pharmaceutical companies like AstraZeneca. By collaborating on research and development initiatives, Vanderbilt can enhance its role in advancing medical innovation and improving patient care.
Vanderbilt can capitalize on the increased investment in U.S. pharmaceutical manufacturing by exploring collaborations with AstraZeneca’s new facility in Virginia. This partnership could lead to joint research projects and educational opportunities for students and faculty.
The focus on reducing drug prices aligns with Vanderbilt’s commitment to healthcare affordability and access. The university can leverage this alignment to advocate for policies that support its mission and enhance its reputation as a leader in healthcare policy and research.

Relevance Score: 4 (The executive order presents significant opportunities for Vanderbilt to engage in healthcare policy, research, and partnerships, requiring major process changes to capitalize on these opportunities.)

Average Relevance Score: 2.2

Timeline for Implementation

Investment Commitment: AstraZeneca is required to invest $50 billion in U.S. manufacturing and research and development by 2030.

This timeline was determined by the explicit directive for AstraZeneca’s investment, which is the only implementation deadline specified.

Relevance Score: 1

Impacted Government Organizations

The White House: As the originating source of the policy, the White House is central to directing the negotiations and implementing the MFN pricing strategy for American patients.
Department of Health and Human Services (HHS): HHS, along with its Centers for Medicare & Medicaid Services (CMS), is directly impacted since every State Medicaid program will receive access to MFN drug prices, influencing federal healthcare policy and cost-savings strategies.
Office of the United States Trade Representative (USTR): Given the emphasis on preventing foreign price controls that undercut American innovation and ensuring repatriation of foreign revenue, USTR’s role in U.S. trade policy is implicated.
Department of the Treasury: The mandate for AstraZeneca to repatriate increased foreign revenue ties into financial oversight, thereby involving Treasury functions related to international revenue and trade finance.

Relevance Score: 2 (A small number of key federal agencies are directly impacted by the order.)

Responsible Officials

N/A – The text directs the Administration broadly without naming any specific officials or agencies responsible for implementation.

Relevance Score: 1 (No specific implementing official is identified, rendering the directive less actionable at individual agency levels.)